TY - JOUR
T1 - Auranofin is an effective agent against clinical isolates of Staphylococcus aureus
AU - Tharmalingam, Nagendran
AU - Ribeiro, Noelly Q.
AU - Da Silva, Danielle L.
AU - Naik, Mandar T.
AU - Cruz, Lana I.B.
AU - Kim, Wooseong
AU - Shen, Steven
AU - Dos Santos, Jéssica D.
AU - Ezikovich, Katarina
AU - D'Agata, Erika M.C.
AU - Mylonakis, Eleftherios
AU - Fuchs, Beth B.
N1 - Publisher Copyright:
© 2019 Newlands Press.
PY - 2019
Y1 - 2019
N2 - Aim: The orphan drug auranofin was recently found to exhibit antimicrobial properties. Materials & methods: We explored the efficacy of auranofin by evaluating the minimal inhibitory concentration against a collection of over 500 clinical isolates derived from multiple institutions, inclusive of drug resistant strains. Our evaluation also included continuous exposure of bacteria to auranofin. Results & conclusion: We found that minimal inhibitory concentrations ranged between 0.125 and 1 mg/l, exerting robust antimicrobial activity against a sizeable clinical collection of the bacteria. Further, we evaluated the propensity of the methicillin-resistant Staphylococcus aureus strain MW2 to develop resistance through extended exposure to auranofin. After 25 days, the bacteria remained susceptible. Our data suggest that resistance mechanisms do not currently exist to block auranofin antimicrobial activity.
AB - Aim: The orphan drug auranofin was recently found to exhibit antimicrobial properties. Materials & methods: We explored the efficacy of auranofin by evaluating the minimal inhibitory concentration against a collection of over 500 clinical isolates derived from multiple institutions, inclusive of drug resistant strains. Our evaluation also included continuous exposure of bacteria to auranofin. Results & conclusion: We found that minimal inhibitory concentrations ranged between 0.125 and 1 mg/l, exerting robust antimicrobial activity against a sizeable clinical collection of the bacteria. Further, we evaluated the propensity of the methicillin-resistant Staphylococcus aureus strain MW2 to develop resistance through extended exposure to auranofin. After 25 days, the bacteria remained susceptible. Our data suggest that resistance mechanisms do not currently exist to block auranofin antimicrobial activity.
KW - MRSA
KW - Staphylococcus aureus
KW - VISA
KW - antimicrobial
KW - auranofin
KW - drug-resistant bacteria
KW - thioredoxin reductase
UR - http://www.scopus.com/inward/record.url?scp=85070402920&partnerID=8YFLogxK
U2 - 10.4155/fmc-2018-0544
DO - 10.4155/fmc-2018-0544
M3 - Article
C2 - 31298580
AN - SCOPUS:85070402920
SN - 1756-8919
VL - 11
SP - 1417
EP - 1425
JO - Future Medicinal Chemistry
JF - Future Medicinal Chemistry
IS - 12
ER -